ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

Stock Information for Lumos Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lumos Pharma Inc.

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
Vyome Announces New Board of Directors with Deep MIT and AI Ties
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.